RU2014140116A - Антитела против pdgf-c - Google Patents

Антитела против pdgf-c Download PDF

Info

Publication number
RU2014140116A
RU2014140116A RU2014140116A RU2014140116A RU2014140116A RU 2014140116 A RU2014140116 A RU 2014140116A RU 2014140116 A RU2014140116 A RU 2014140116A RU 2014140116 A RU2014140116 A RU 2014140116A RU 2014140116 A RU2014140116 A RU 2014140116A
Authority
RU
Russia
Prior art keywords
seq
antibody
amino acid
cdr
heavy chain
Prior art date
Application number
RU2014140116A
Other languages
English (en)
Russian (ru)
Inventor
Клаудия ФРОМОНД
Хоа Ту НГО
Ричард ЗВАЛ
Софи НОТЕБАРТ
Original Assignee
Тромбодженикс Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тромбодженикс Н.В. filed Critical Тромбодженикс Н.В.
Publication of RU2014140116A publication Critical patent/RU2014140116A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014140116A 2012-04-24 2013-04-24 Антитела против pdgf-c RU2014140116A (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261637372P 2012-04-24 2012-04-24
US61/637,372 2012-04-24
EP12165314.1 2012-04-24
EP12165314 2012-04-24
US201261727231P 2012-11-16 2012-11-16
EP12192943.4 2012-11-16
EP12192943 2012-11-16
US61/727,231 2012-11-16
PCT/EP2013/058513 WO2013160359A1 (en) 2012-04-24 2013-04-24 Anti-pdgf-c antibodies

Publications (1)

Publication Number Publication Date
RU2014140116A true RU2014140116A (ru) 2016-06-10

Family

ID=49482233

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014140116A RU2014140116A (ru) 2012-04-24 2013-04-24 Антитела против pdgf-c

Country Status (13)

Country Link
US (1) US9884910B2 (enExample)
EP (1) EP2841454A1 (enExample)
JP (1) JP2015515487A (enExample)
KR (1) KR20150005631A (enExample)
CN (1) CN104321343A (enExample)
AU (1) AU2013254690B2 (enExample)
BR (1) BR112014025560A2 (enExample)
CA (1) CA2871528A1 (enExample)
IN (1) IN2014DN09717A (enExample)
MX (1) MX2014012843A (enExample)
NZ (2) NZ700274A (enExample)
RU (1) RU2014140116A (enExample)
WO (1) WO2013160359A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013254690B2 (en) 2012-04-24 2017-12-07 Thrombogenics N.V. Anti-PDGF-C antibodies
US11633382B2 (en) 2015-11-10 2023-04-25 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
US11390661B2 (en) 2016-06-27 2022-07-19 Aicuris Anti-Infective Cures Gmbh HCMV entry inhibitors
US11352420B2 (en) 2016-07-01 2022-06-07 Paracrine Therapeutics Ab Methods and compositions for PDGF-CC inhibition
KR101943083B1 (ko) 2017-03-30 2019-01-29 (주)케어젠 환경오염 물질에 대한 세포 보호 효과를 갖는 펩타이드 및 이의 용도
KR101943081B1 (ko) 2017-08-31 2019-01-29 (주)케어젠 주름 개선 활성을 나타내는 펩타이드 및 이의 용도
PL3720428T3 (pl) * 2017-12-04 2023-05-08 Laboratorios Salvat, S.A. Kompozycja oftalmiczna do podawania miejscowego zawierająca kwas dobezylowy do leczenia chorób tylnego odcinka oka
KR102726837B1 (ko) * 2021-09-29 2024-11-07 (주)케어젠 항노화 활성을 갖는 펩타이드 및 이의 용도
US20250051435A1 (en) * 2023-08-11 2025-02-13 Invetx, Inc. Anti-il-5 antibodies and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
WO1991019515A1 (en) 1990-06-21 1991-12-26 The Board Of Trustees Of The Leland Stanford Junior University Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5304118A (en) 1992-12-16 1994-04-19 Trese Michael T Method for performing a vitrectomy on an eye
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
EP1064382B1 (en) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
CA2344561A1 (en) 1998-09-30 2000-04-06 Ludwig Institute For Cancer Research Platelet-derived growth factor c, dna coding therefor, and uses thereof
US6432673B1 (en) * 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
DE69939330D1 (de) 1998-12-07 2008-09-25 Zymogenetics Inc Wachstumsfaktor-homologe zvegf-3
AU8031700A (en) 1999-10-21 2001-04-30 Zymogenetics Inc. Method of treating fibrosis
JP2003533675A (ja) * 2000-03-28 2003-11-11 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 血小板由来成長因子ｃ（ｐｄｇｆ−ｃ）を発現する非ヒトトランスジェニック動物およびそれらの使用
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
EP1660135B1 (en) 2003-07-25 2009-06-03 ZymoGenetics, Inc. Method of treating hepatocellular carcinoma
US20050282233A1 (en) 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
US8147828B2 (en) * 2006-04-17 2012-04-03 Ludwig Institute For Cancer Research Methods and compositions for modulation of blood-neural barrier
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
WO2010033913A1 (en) 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
AU2013254690B2 (en) 2012-04-24 2017-12-07 Thrombogenics N.V. Anti-PDGF-C antibodies

Also Published As

Publication number Publication date
CA2871528A1 (en) 2013-10-31
JP2015515487A (ja) 2015-05-28
WO2013160359A1 (en) 2013-10-31
US20150232546A1 (en) 2015-08-20
CN104321343A (zh) 2015-01-28
IN2014DN09717A (enExample) 2015-07-31
KR20150005631A (ko) 2015-01-14
US9884910B2 (en) 2018-02-06
MX2014012843A (es) 2017-01-23
EP2841454A1 (en) 2015-03-04
NZ724395A (en) 2018-03-23
AU2013254690B2 (en) 2017-12-07
BR112014025560A2 (pt) 2017-07-04
NZ700274A (en) 2016-10-28
AU2013254690A1 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
JP7464764B2 (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
CA3168654A1 (en) Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
JP2021524267A5 (enExample)
RU2014151788A (ru) Молекула, специфически связывающаяся с rsv
CN111148761A (zh) 多特异性抗体及其制备和使用方法
JP2018529667A (ja) Ｔ細胞媒介免疫応答を調節するための組成物および方法
RU2014109039A (ru) Биспецифические антигенсвязывающие молекулы
RU2013125459A (ru) АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met
JP2018527919A5 (enExample)
JP7757347B2 (ja) 操作された抗ｉｌ－２抗体
RU2013143358A (ru) Анти-fgfr4 антитела и способы их применения
JP2017534253A5 (enExample)
JP2018500014A5 (enExample)
JP2020517248A (ja) Ｌｒｉｇ‐１タンパク質に特異的な結合分子およびその用途
RU2015118180A (ru) Антитела к бета-амилоиду
CN116948035A (zh) 多特异性抗体及其制备和使用方法
RU2019134462A (ru) Антитела, связывающиеся с steap-1
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
FI3684813T3 (fi) Agonistisia CD40-vasta-aineita
JP2021524255A5 (enExample)
JP2020533965A5 (enExample)
RU2014109093A (ru) Антитела против нейрегулина и их применение
RU2015108797A (ru) Антитела к jagged и способы их применения перекрестная ссылка на родственные заявки

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180206